MYBL2 Antibody, FITC conjugated

1. results suggest that B-Myb-A3B contributes to DNA damage and could be targeted by inhibiting EGF receptor. PMID: 28276478
2. The structure and biochemical analysis provide an understanding of how oncogenic B-Myb is recruited to regulate genes required for cell-cycle progression, and the MMB interface presents a potential therapeutic target to inhibit cancer cell proliferation. PMID: 30224471
3. B-Myb is an independent prognostic marker and serves as a potential target in the diagnosis and/or treatment of NSCLC, and that B-Myb functions as a tumor-promoting gene by targeting IGFBP3 in NSCLC cells. PMID: 29772705
4. MYBL2 is a key downstream factor of Akt/FoxM1 signaling to promote progression of human glioma, and could be a new candidate gene for molecular targeting therapy and biomarker for radiotherapy of glioma. PMID: 28784180
5. These results suggested that overexpression of MYBL2 might serve as a novel prognostic biomarker in pancreatic ductal adenocarcinoma patients PMID: 28559119
6. A total of 41 differentially expressed genes, such as SOCS3, VAPA, and COL5A2, are speculated to have roles in the pathogenesis of acute myocardial infarction; 2 transcription factors FOXO3 and MYBL2, and 2 miRNAs hsa-miR-21-5p and hsa-miR-30c-5p may be involved in the regulation of the expression of these differentially expressed genes. PMID: 29049183
7. Results suggested that the oncogenic transcription factor HIF-2alpha stabilized VHL disease suppressor B-Myb, which is also a transcription factor, by physical interaction. Some B-Myb-dependent gene expression was similarly affected by B-Myb or HIF-2alpha knockdown, suggesting that stabilization of B-Myb by HIF-2alpha may play a role in specific gene expressions. PMID: 28394947
8. The MuvB multiprotein complex, together with B-MYB and FOXM1 (MMB-FOXM1) regulate the expression of mitotic kinesins in breast cancer cells. PMID: 28061449
9. MYBL2 overexpression promotes Gallbladder Cancer cell proliferation through the regulation of the cell cycle at the S and G2/M phase transitions. Thus, MYBL2 could serve as a potential prognostic and therapeutic biomarker in Gallbladder Cancer patients. PMID: 28427077
10. Study identified B-Myb as a substrate of the pVHL ubiquitin ligase complex, which targets it for degradation via the ubiquitin-proteasome pathway. It also, provide evidence that the regulation of B-Myb by pVHL plays a critical role in von Hippel-Lindau disease. PMID: 27090638
11. Data indicate that gene expression alterations in endometrial carcinoma samples with high ATAD2 expression showed upregulation of several cancer-related genes including B-MYB gene. PMID: 26308378
12. We found that B-Myb upregulated expression of the key epithelial-to-mesenchymal transition regulator snail and that it mediated epithelial-to-mesenchymal transition activation and cell invasion by B-Myb. PMID: 25502082
13. conclude that downregulation of MYBL2 activity below levels predicted by classical haploinsufficiency underlies the clonal expansion of hematopoietic progenitors in a large fraction of human myeloid malignancies PMID: 23878725
14. B-Myb plays a role in suppression of keratinocyte differentiation and maintenance of the undifferentiated proliferative phenotype by modulating the expression levels of cell cycle regulatory proteins, expressed in the S and G2/M phases of the cell cycle PMID: 24515894
15. Results show that E7 interacts with the B-Myb, FoxM1 and LIN9 components of this activator complex, leading to cooperative transcriptional activation of mitotic genes in primary cells and E7 recruitment to the corresponding promoters. PMID: 24141769
16. MYBL2 expression analysis could be useful to define subgroups of patients with poor prognosis. PMID: 24199710
17. MALAT1-depleted cells display reduced expression of B-MYB (Mybl2), an oncogenic transcription factor involved in G2/M progression, due to altered binding of splicing factors on B-MYB pre-mRNA and aberrant alternative splicing PMID: 23555285
18. Low MYBL2 expression is associated with haematopoietic neoplasia. PMID: 22910183
19. A novel role for B-Myb in S-phase that appears to be independent of its sequence-specific DNA-binding activity and its ability to stimulate the expression of bona fide B-Myb target genes. PMID: 23032261
20. Mybl2 upregulation induces fast growth and progression of premalignant and malignant liver, through cell cycle deregulation and activation of genes and pathways related to tumor progression. PMID: 21419759
21. Owing to the role of B-Myb and E2F1 transcription factors in controlling cell-cycle progression of leukemic cells, the downregulation of these oncogenes by miR-34a suggests the usefulness of therapeutic approaches aimed to modulate the levels of miR-34a. PMID: 21367750
22. study concludes that MYCN and B-MYB are engaged in a reciprocal regulatory loop whose pharmacological targeting could be beneficial to patients with the aggressive forms of cancer in which MYCN is amplified PMID: 21304178
23. MYBL2 activation is crucial for human HCC progression. In particular, our data indicate that MYBL2-LIN9 complex integrity contributes to survival of DNA damaged p53(-/-) cells. PMID: 21480327
24. B-MYB acts as a positive regulator of STRAP PMID: 21148321
25. B-MYB represses p16(INK4alpha)by binding to a MYB-binding site within the promoter region. PMID: 20734103
26. miR-29 and miR-30 regulate B-Myb expression by binding to its 3'UTR; these microRNAs play an important role in Rb-driven cellular senescence PMID: 21187425
27. Data show that that ANCCA is crucial for proliferation and survival of triple-negative/basal-like cancer cells and that it controls the expression of B-Myb and histone methyltransferase EZH2. PMID: 20864510
28. These data suggest that Mybl2 plays a subtle but key role in linking specific aspects of cell-cycle progression with generation of signals for differentiation. PMID: 20857481
29. Study identified an overrepresentation of focal amplifications of known (FGFR3, CCND1, MYC, MDM2) and novel candidate genes (MYBL2, YWHAB and SDC4) in stage Ta bladder carcinoma. PMID: 19821490
30. B-Myb transactivates the IGFBP-5 promoter PMID: 11973331
31. ZPR9 plays an important role in modulation of the transactivation by B-MYB and cellular growth of neuroblastoma cells PMID: 12645566
32. B-Myb repressor function is regulated by cyclin A phosphorylation and sequences within the C-terminal domain. PMID: 12673206
33. it is evident that B-Myb protein may promote cell proliferation by a non-transcriptional mechanism that involves release of active cyclin/cyclin dependent kinase 2 from cyclin-dependent inhibitor 1C p57(KIP2) PMID: 12947099
34. MRGX can repress or activate the B-myb promoter depending on the cell type studied, suggesting that there may be tissue-specific functions of this protein PMID: 14506250
35. B-Myb has a role in regulation of c-Myc expression by cytosolic phospholipase A2 PMID: 14769798
36. Human B-Myb reduces neointima formation after vascular injury in transgenic mice. PMID: 15256398
37. regulated by temperature to activate genes required for cell survival. PMID: 15618219
38. overexpressed during the S phase of the cell cycle compared with the G0/1 phase PMID: 16476973
39. Chromosomal fragmentation and other aberrations, including shorter, thicker chromatids, end-to-end fusion, and loss of a chromatid, suggest that reduced B-Myb activity is also associated with structural chromosomal instability. PMID: 16551698
40. Mip/LIN-9 is required for the expression of B-Myb, and both proteins collaborate in the control of the cell cycle progression via the regulation of S phase and cyclin A, cyclin B, and CDK1 PMID: 17098733
41. human LIN-9, together with B-MYB, has a critical role in the activation of genes that are essential for progression into mitosis PMID: 17159899
42. The repressor complex that Mip/LIN-9 forms with p107 takes functional precedence over the transcriptional activation linked to the Mip/LIN-9 and B-Myb interaction. PMID: 17563750
43. The expression of stable, hypophosphorylated B-MYB in neuroblastoma may promote cell survival and induce aggressive tumour growth. PMID: 17588787
44. Some B-MYB alleles might be associated with a reduced risk of developing neoplastic disease. PMID: 18026132
45. MYBL2 gene expression was significantly higher in colorectal cancer patients than in healthy volunteers. PMID: 19016757
46. Insight into the influence of B-Myb in human breast cancer, which is of potential clinical importance for determining disease risk and for guiding treatment. PMID: 19043454
47. B-MYB fails to dissociate from LINC in p53 mutant cells, that this contributes to increased G(2)-M gene expression in response to DNA damage, and that B-MYB is required for recovery from the G(2) DNA damage checkpoint in p53-negative cells. PMID: 19383908

Show More

Hide All

HGNC: 7548

OMIM: 601415

KEGG: hsa:4605

STRING: 9606.ENSP00000217026

UniGene: Hs.179718